Du är här

2016-02-04

Prothena Corporation plc: Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18

DUBLIN, Ireland, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein
immunotherapies, announced today that it will report its fourth quarter and
full year 2015 financial results on Thursday, February 18, 2016, after the
close of the U.S. financial markets. The announcement will be followed by a
live audio webcast and conference call at 4:30 PM ET.

The webcast will be made available on the Company's website at
www.prothena.com under the Investors tab in the Events and Presentations
section. Following the live audio webcast, a replay will be available on the
Company's website for at least 90 days.

To access the call via dial-in, please dial (877) 887-5215 (U.S. toll free) or
(315) 625-3069 (international) five minutes prior to the start time and refer
to conference ID number 33151950. A replay of the call will be available
until February 25, 2016 via dial-in at (855) 859-2056 (U.S. toll free) or
(404) 537-3406 (international), Conference ID Number 33151950.

Separately, Prothena's presentation time at the upcoming Leerink Partners 5th
Annual Global Healthcare Conference

on February 11, 2016 has changed. Prothena will participate in a fireside
chat at 9:20 AM ET in New York, NY. The event will be webcast and available
on the Company's website atwww.prothena.com under the Investors tab in the
Events and Presentations section.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company
focused on the discovery, development and commercialization of novel protein
immunotherapies for the potential treatment of diseases that involve amyloid
or cell adhesion. The company is developing antibody-based product candidates
that target a number of potential indications including AL amyloidosis
(NEOD001), Parkinson's disease and other related synucleinopathies (PRX002),
and psoriasis and other inflammatory diseases (PRX003).

For more information, please visit the company's web site at www.prothena.com.
Contacts
Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com

Media: Ellen Rose
650-922-2405, ellen.rose@prothena.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via Globenewswire

HUG#1983576

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.